By: ABRS- Academic Team
Introduction
Outsourcing decisions in clinical research are often discussed in terms of cost, flexibility, and access to specialized expertise. However, for clinical trial sponsors, one of the most important questions is more fundamental: which outsourcing approach best fits the organization’s existing capabilities and the operational requirements of its clinical development program?
A sponsor may already have established clinical operations teams, internal procedures, and systems for managing studies but lack sufficient professionals to support a growing portfolio. Another organization may have limited clinical infrastructure and require an external partner to coordinate multiple activities, from study start-up through closeout.
Although both organizations need external support, their operational requirements are different. The first may benefit from a Functional Service Provider (FSP) arrangement, while the second may be better positioned to use a full-service Contract Research Organization (CRO).
The distinction is not necessarily between two different types of service providers. CROs can deliver both full-service and functional outsourcing solutions. The difference lies primarily in the scope of responsibilities, the management structure, and how the provider’s services integrate with the sponsor’s organization.
In the 2023 analysis Outsourcing Model Usage and its Relationship to Clinical Trial Performance, published in Applied Clinical Trials, Lamberti and colleagues explain that clinical research outsourcing has evolved beyond traditional full-service and functional classifications. Their research identifies considerable variation in how sponsors distribute responsibilities, use external infrastructure, and establish operational accountability.
These findings suggest that choosing an outsourcing model should begin with an assessment of what the sponsor can already manage and where additional capabilities are required.
An FSP model may be particularly appropriate when an organization wants to strengthen specific clinical research functions without transferring the broader management of its studies. Understanding when this arrangement is suitable requires examining internal readiness, functional resource needs, and the responsibilities the sponsor intends to retain.
When Sponsors Have Established Clinical Operations but Need Additional Functional Capacity
One of the clearest situations in which an FSP model may be appropriate is when a sponsor already has the infrastructure necessary to manage clinical trials but requires additional personnel or expertise to execute selected activities.
An established sponsor may have experienced Clinical Trial Managers, documented standard operating procedures (SOPs), clinical trial management systems, and established processes for vendor oversight. These resources provide an internal framework for directing studies and evaluating operational performance.
However, maintaining this infrastructure does not necessarily mean the organization has sufficient capacity to perform every required function.
For example, a sponsor may manage several studies simultaneously and need additional Clinical Research Associates (CRAs) to support investigative sites in different countries. Outsourcing the management of an entire trial may not be necessary when the organization primarily requires additional monitoring capabilities.
An FSP arrangement can address this situation by providing qualified professionals who perform defined activities within the sponsor’s existing operational structure.
In the 2021 peer-reviewed publication Vendor Selection & Management, published in the Journal of the Society for Clinical Data Management, Amatya and Edgerton describe functional outsourcing as an arrangement in which sponsors may obtain selected services while retaining project ownership internally. The authors also discuss the ability to adjust external resources according to development activity.
This distinction is relevant because the sponsor’s internal capabilities influence the type of external support it requires.
Under an FSP arrangement, professionals may use the sponsor’s established systems, follow its relevant procedures, and communicate through designated management channels. The external provider may also contribute functional management, training, resource coordination, and performance support, depending on the agreement.
The sponsor can therefore maintain its existing trial management structure while expanding the capacity available to perform specific activities.
For example, a sponsor with an established clinical operations department may need regional monitoring support during the activation and enrollment phases of a multinational study. If its internal team can coordinate monitoring strategy, review findings, and manage operational decisions, an FSP arrangement may provide the necessary regional resources without introducing a separate full-service study management structure.
The availability of internal resources, however, should not be confused with readiness to manage external professionals. The sponsor must also have sufficient capacity to coordinate activities, provide appropriate training, address escalations, and oversee performance.
The ICH E6(R3) Good Clinical Practice guideline provides an important framework for these responsibilities. Section 3.6.4 addresses the documentation of activities transferred to service providers, while Section 3.6.6 establishes that the sponsor retains ultimate responsibility for its trial-related activities, including participant protection and the reliability of trial data.
Therefore, an FSP model is particularly relevant when a sponsor can combine external functional expertise with the management and oversight capabilities already established within its organization.
When Specific Expertise, Portfolio Growth, or Regional Expansion Requires Targeted Support
A second situation favoring an FSP approach arises when a sponsor needs specialized capabilities that are not consistently available within its internal teams.
Clinical development programs can require different combinations of professional expertise depending on the study phase, therapeutic area, geographic coverage, and operational complexity. A sponsor may have sufficient internal personnel for routine activities but require additional support for a particular function or region.
For example, an organization entering new research markets may need professionals familiar with regional site practices, local operational requirements, and applicable clinical research regulations. Another organization may require additional pharmacovigilance personnel or specialized study start-up support during a period of increased clinical activity.
In these circumstances, the sponsor may not need to transfer the management of an entire study. Instead, it can evaluate whether the missing capability can be addressed through a defined functional service arrangement.
The 2023 outsourcing analysis by Lamberti and colleagues examined outsourcing practices across 117 pivotal clinical trials contributed by nine sponsor companies. The authors found that functional outsourcing was frequently used for activities such as clinical monitoring and data management, while other functions were more commonly retained internally.
The study’s sample was concentrated in large pharmaceutical organizations and primarily included Phase III trials. Its findings should therefore not be generalized to every clinical development organization. Nevertheless, the analysis illustrates how sponsors use different sourcing arrangements according to functional requirements rather than applying one model uniformly to every activity.
Consider a hypothetical pharmaceutical company managing an international portfolio of studies.
Its internal clinical operations team has established procedures, systems, and experienced study managers. However, the company is preparing to activate additional investigative sites in Latin America and requires qualified monitoring professionals in several countries.
A full-service CRO arrangement could provide comprehensive external study management, but that broader scope may overlap with functions the sponsor already performs internally.
An FSP arrangement could instead provide regional CRAs who support monitoring activities while working with the sponsor’s existing clinical management team.
This structure may help the organization extend its regional capabilities while preserving established operational procedures and communication channels.
A similar consideration applies when functional requirements change across several studies.
For example, a sponsor may experience increased monitoring activity during enrollment, followed by different documentation and closeout requirements later in the program. An FSP partnership may allow resource assignments to be reviewed and adjusted as these needs evolve, subject to availability, qualification, contractual terms, and continuity requirements.
The potential value is not simply obtaining more personnel. It is having an operational arrangement that can connect specialized expertise to the sponsor’s ongoing clinical development activities.
However, the ability to coordinate multiple service providers should also be considered.
The 2020 peer-reviewed study Assessing Outsourcing Oversight Practices and Performance, published in Therapeutic Innovation & Regulatory Science, examines outsourcing oversight practices and identifies opportunities to strengthen management involvement, communication, collaboration, and performance oversight.
These findings reinforce an important consideration for sponsors: additional functional capabilities must be accompanied by appropriate operational coordination.
An FSP model may therefore be especially useful when the sponsor has a well-defined functional need, sufficient internal management capacity, and a clear process for integrating external professionals into its operations.
When an FSP Partnership Fits Sponsor-Led Clinical Operations
Choosing an FSP model becomes particularly relevant when a sponsor has identified the clinical research activities it intends to manage internally and needs an external partner to reinforce the functions required for execution.
At this point, the outsourcing decision is no longer simply about obtaining additional personnel. It involves determining whether specialized professionals can be integrated into the sponsor’s established processes while maintaining appropriate coordination, operational visibility, and oversight.
A sponsor considering an FSP arrangement should first determine whether it has the internal leadership and management structure necessary to direct the assigned clinical activities.
For example, an organization with established Clinical Trial Managers, monitoring plans, standard operating procedures, and quality management processes may be well positioned to integrate external monitoring professionals into its existing operations.
The next consideration is whether the activities requiring external support are sufficiently defined.
A sponsor seeking additional CRAs, study start-up specialists, auditors, or other qualified professionals should be able to identify the expected scope of work, required competencies, reporting relationships, and relevant deliverables. These elements help establish how the external professionals will contribute to the study and how their performance will be assessed.
The Vendor Selection & Management guidance emphasizes that outsourcing arrangements should establish clearly defined services, governance structures, communication channels, and escalation procedures. The publication also discusses how FSP and strategic outsourcing partnerships may require coordination at multiple organizational levels.
These considerations help distinguish an integrated functional partnership from an arrangement focused exclusively on personnel availability.
In an FSP model, external professionals may become familiar with the sponsor’s operating environment and contribute to different studies within the same clinical development portfolio. When appropriately planned, this can support continuity in functional knowledge, processes, and communication.
Consider a hypothetical sponsor managing several clinical trials across different regions. Its internal teams retain responsibility for study strategy and overall management, but the organization requires monitoring professionals in multiple countries and specialized audit support during selected phases.
Rather than transferring these studies to a full-service provider, the sponsor may establish an FSP partnership to obtain the specific functional capabilities required.
The external professionals would carry out their assigned activities according to the agreed procedures and responsibilities. Sponsor personnel would continue directing the retained operational functions, reviewing relevant information, and making decisions within their established authority.
The effectiveness of this structure would depend on how well the external professionals are selected, trained, integrated, and supervised.
This approach also creates an opportunity to establish continuity across the clinical development portfolio. As new studies begin or existing studies progress, the sponsor and FSP provider can evaluate whether qualified professionals can be assigned to emerging functional needs without unnecessarily duplicating operational structures.
However, resource flexibility should not be interpreted as unlimited availability. Changes in assignments depend on professional qualifications, contractual arrangements, personnel capacity, and the need to maintain continuity in trial activities.
Another important consideration is how the FSP relationship supports quality management and oversight.
The ICH E6(R3) Good Clinical Practice guideline addresses the sponsor’s responsibility to assess the suitability of service providers, maintain access to relevant information, and exercise appropriate oversight over important transferred activities. These principles are particularly relevant when specialized professionals operate within a sponsor-led clinical research structure.
Similarly, the FDA’s 2023 guidance on risk-based monitoring provides recommendations for planning monitoring activities, identifying important risks, and communicating monitoring findings. Although the guidance does not prescribe an outsourcing model, its recommendations illustrate the importance of maintaining clearly defined monitoring and reporting processes.
For an FSP arrangement, these requirements point toward the importance of connecting functional execution with the sponsor’s quality management and operational decision-making processes.
The potential advantage is not that the provider assumes responsibility for every aspect of trial management. Rather, the provider contributes specialized capabilities while the sponsor maintains the responsibilities and operational authority established under the agreement and applicable requirements.
This distinction is central to the FullSpectrum FSP model offered by Advanced BioResearch Solutions (ABRS).
The model is designed to provide tailored functional support for sponsors and CROs through qualified clinical research professionals, regional operational expertise, and integration with established sponsor processes.
Depending on the study’s requirements and the agreed scope of services, this support may include clinical monitoring, auditing, regulatory activities, pharmacovigilance, and Clinical Oversight Management (COM).
The FullSpectrum FSP approach emphasizes the alignment of professional resources with sponsor-led operations, allowing organizations to obtain functional support while retaining defined responsibilities for clinical development strategy and decision-making.
For sponsors evaluating whether an FSP partnership is suitable, the central consideration is whether external expertise can be integrated into an operating model that already has the capacity to direct, coordinate, and oversee clinical trial execution.
When these conditions are present, an FSP arrangement can offer a structured way to strengthen clinical research capabilities without requiring a complete reorganization of the sponsor’s existing operational framework.
Conclusion:
The decision to select a Functional Service Provider model should begin with an assessment of the sponsor’s existing clinical operations capabilities and the specific requirements of its development program.
An FSP arrangement may be particularly appropriate when an organization already has established study management processes, clinical systems, and governance structures but requires additional functional capacity, specialized expertise, or regional support.
In these circumstances, functional outsourcing can allow sponsors to reinforce selected clinical research activities while maintaining continuity with their internal operational processes and responsibilities.
The suitability of the model also depends on whether the sponsor can define the activities to be performed, integrate qualified external professionals, establish effective communication channels, and maintain appropriate oversight. Without these elements, the potential advantages of functional outsourcing may be difficult to realize.
For organizations managing several clinical trials or expanding into new research regions, an FSP partnership may provide a framework for aligning specialized capabilities with changing operational demands. Its value, however, depends on the quality of implementation rather than the outsourcing model alone.
Through its FullSpectrum FSP approach, ABRS supports sponsor-led clinical development by connecting qualified clinical research professionals with defined operational needs, regional expertise, and structured oversight arrangements.
Ultimately, the FSP model becomes a particularly relevant choice when a sponsor does not need to outsource the broader management of its clinical trials but does need the specialized capabilities required to execute them effectively.
The purpose of an FSP partnership is therefore not to replace the sponsor’s existing strengths, but to complement them through targeted functional expertise, operational integration, and clearly defined accountability.